Search

Displaying results 4351 - 4360 of 10000 in total
  1. Target

    Transforming growth factor beta activator LRRC32

    go.drugbank.com/bio_entities/BE0014554
    TargetHumans

    Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19651619, PubMed:19750484, PubMed:22278742). As...

    Synonyms: Leucine-rich repeat-containing protein 32Function: receptor ligand inhibitor activity
  2. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal … Triclocarban, with the chemical formula C13H9Cl3N2O [L2675] is an antibacterial agent that is particularly effective against Gram-positive bacteria such as *Staphylococcus aureus*.

  3. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

    Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Agonists
  4. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

    Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor Antagonist
  5. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

  6. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  7. Drug

    Icaridin

    go.drugbank.com/drugs/DB14074
    Investigational

    It is considered to be the first choice of repellent by the Public Health Agency of Canada’s Canadian Advisory Committee on Tropical Medicine and Travel for travelers six months to 12 years of age [A39203 … Icaridin is reported to be less irritating than [Diethyltoluamide], another common insect repellant, and products containing up to 20% of icaridin are considered safe for long-term use in adults [A39231

  8. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    The vaccine comprises purified rsPSMA protein formulated with Alhydrogel® adjuvant. … entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003).

  9. Drug

    Apronalide

    go.drugbank.com/drugs/DB13221
    Approved

    Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].

  10. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.